The study included 131 patients with relapsed CRC and showed that ColveraTM had a significantly higher sensitivity for detecting CRC recurrence then CEA (68.1% vs. 31.9%; p < 0.001) with a similar specificity (97.6% vs. 96.4%; p = 0.6547). Here, CEACAM5 is linked to colorectal carcinoma.